Cover Image
市場調查報告書

基質細胞衍生因子1:開發中產品分析

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364868
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
基質細胞衍生因子1:開發中產品分析 Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 62 Pages
簡介

本報告提供以基質細胞衍生因子1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

基質細胞衍生因子1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Juventas Therapeutics, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • TikoMed AB

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0171TDB

Summary

Global Markets Direct's, 'Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H1 2016', provides in depth analysis on Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted pipeline therapeutics.

The report provides comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12)
  • The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) Overview
  • Therapeutics Development
    • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Products under Development by Stage of Development
    • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Products under Development by Therapy Area
    • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Products under Development by Indication
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Products under Development by Companies
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Products under Development by Universities/Institutes
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
    • Juventas Therapeutics, Inc.
    • Momenta Pharmaceuticals, Inc.
    • Noxxon Pharma AG
    • TikoMed AB
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Drug Profiles
    • Genistein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBsolvMIR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • necuparanib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaptesed pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Dormant Projects
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced in Hepatomas or SDF1 or Pre B cell Growth Stimulating Factor or CXCL12) - Featured News & Press Releases
    • Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
    • May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
    • Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease
    • Jan 20, 2016: NOXXON Pharma Hosts Key Opinion Leader Symposium
    • Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
    • Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
    • Jun 16, 2015: Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy
    • Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
    • May 26, 2015: Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treatment
    • May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting
    • Dec 05, 2014: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference
    • Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
    • Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia
    • Nov 12, 2014: Juventas Therapeutics Phase II Clinical Study Results to be Presented at 2014 American Heart Association Scientific Sessions
    • Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Pipeline by Noxxon Pharma AG, H1 2016
  • Pipeline by TikoMed AB, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top